MX2022003912A - Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica. - Google Patents

Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica.

Info

Publication number
MX2022003912A
MX2022003912A MX2022003912A MX2022003912A MX2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A MX 2022003912 A MX2022003912 A MX 2022003912A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
prevention
treatment
product
acquired hemophilia
Prior art date
Application number
MX2022003912A
Other languages
English (en)
Inventor
Koichiro Yoneyama
Sayaka Nagami
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority claimed from PCT/JP2020/038069 external-priority patent/WO2021070885A1/ja
Publication of MX2022003912A publication Critical patent/MX2022003912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los presentes inventores descubrieron que la administración de una composición farmacéutica que comprende emicizumab de acuerdo con un régimen de administración predeterminado tiene el potencial de prevenir y/o tratar eficazmente la hemofilia A adquirida.
MX2022003912A 2019-10-11 2020-10-08 Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica. MX2022003912A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019188099 2019-10-11
JP2020011992 2020-01-28
PCT/JP2020/038069 WO2021070885A1 (ja) 2019-10-11 2020-10-08 後天性血友病ａの予防および／または治療に用いられる医薬組成物、および当該医薬組成物を含む製品

Publications (1)

Publication Number Publication Date
MX2022003912A true MX2022003912A (es) 2022-04-20

Family

ID=74673603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003912A MX2022003912A (es) 2019-10-11 2020-10-08 Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica.

Country Status (10)

Country Link
US (1) US20220305122A1 (es)
EP (1) EP4043033A4 (es)
JP (1) JP6836696B1 (es)
KR (1) KR20220082000A (es)
CN (1) CN114599391A (es)
AU (1) AU2020364698A1 (es)
CA (1) CA3152701A1 (es)
CR (1) CR20220198A (es)
IL (1) IL292106A (es)
MX (1) MX2022003912A (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
JPWO2005035754A1 (ja) 2003-10-14 2006-12-21 中外製薬株式会社 機能蛋白質を代替する二種特異性抗体
SI1876236T1 (sl) 2005-04-08 2014-11-28 Chugai Seiyaku Kabushiki Kaisha Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi
EP2644698B1 (en) 2010-11-17 2018-01-03 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TWI831106B (zh) * 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
MX2019002510A (es) * 2016-09-06 2019-06-24 Chugai Pharmaceutical Co Ltd Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.

Also Published As

Publication number Publication date
CA3152701A1 (en) 2021-04-15
CR20220198A (es) 2022-06-06
JPWO2021070885A1 (es) 2021-04-15
IL292106A (en) 2022-06-01
AU2020364698A1 (en) 2022-04-21
EP4043033A4 (en) 2023-11-08
US20220305122A1 (en) 2022-09-29
JP6836696B1 (ja) 2021-03-03
EP4043033A1 (en) 2022-08-17
CN114599391A (zh) 2022-06-07
KR20220082000A (ko) 2022-06-16

Similar Documents

Publication Publication Date Title
PH12018500642A1 (en) Anti-garp antibody
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MY187540A (en) Compounds active towards bromodomains
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP4299129A3 (en) Dosing regimen for treatment of cognitive impairments with blood plasma products
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12021550237A1 (en) Bioavailable oral dosage forms.
CR20220355A (es) Compuestos activos frente a receptores nucleares
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
CR20220198A (es) Composición farmacéutica que puede usarse para la prevención y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composición farmacéutica
WO2018030881A3 (ko) 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도
PH12017501918A1 (en) Multi-peptide composition
WO2017010673A3 (ko) 혈관누수 증후군의 예방 또는 치료용 조성물
MX2023005681A (es) Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol.
WO2018132160A3 (en) Methods of treating or preventing type 1 diabetes
MX2018009921A (es) Composición farmacéutica para prevenir y tratar trastornos del sueño.
WO2017037578A3 (en) Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
MX2017001512A (es) Compuestos activos hacia bromodominios.